IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
MedPage Today) — The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday. The tablets are indicated…
MedPage Today) — The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.
The tablets are indicated…
Read More